HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

leucylleucine (Leu-Leu)

Subscribe to New Research on leucylleucine

RN given refers to (DL-Leu-DL-Leu)-isomer

Also Known As:

Leu-Leu; L-leucyl-L-leucine; leucyl-leucine; leucylleucine monohydrochloride, (L-Leu-L-Leu)-isomer; leucylleucine, (D-Leu-D-Leu)-isomer; leucylleucine, (L-Leu-D-Leu)-isomer; leucylleucine, (L-Leu-L-Leu)-isomer

Networked: 83 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Peptides: 22950
  - Oligopeptides: 168
    - Dipeptides: 137
      - leucylleucine: 83

Experts

1.	Skotland, Tore: 2 articles (11/2007 - 01/2006)
2.	Oulie, Inger: 2 articles (11/2007 - 01/2006)
3.	Mohr, Lena K M: 1 article (10/2015)
4.	Krohne, Tim U: 1 article (10/2015)
5.	Brandstetter, Carolina: 1 article (10/2015)
6.	Hoffmann, Andrea V: 1 article (10/2015)
7.	Holz, Frank G: 1 article (10/2015)
8.	Chen, Zhiping: 1 article (10/2014)
9.	Peng, Qiliu: 1 article (10/2014)
10.	Lao, Xianjun: 1 article (10/2014)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2014 - "We found that cancer cells exposed to n-acetyl-leu-leu-norleucinal (ALLN) treatment and UbcH10 depletion exhibit a synergistic therapeutic effect. " 09/01/2011 - "With respect to tumor stage, Leu/Leu genotype was more frequent in patients with high stage disease than those of low stage disease. " 06/01/2011 - "The mutant genotype (Leu/Leu) of HPC/ELAC-2 was present in 9.6, 7.6 and 5.9% of BPH, cancer cases and healthy controls, respectively. " 10/01/1991 - "Nine indolactam congeners with L-Abu, gamma,delta-delta-Nva, Nva, Phg, tert-Leu, Leu, Ile, allo-Ile, Nle, instead of L-Val in (--)-indolactam-Val, were synthesized by microbial conversion and examined using two biological tests related to tumor promotion. " 09/01/2012 - "When stratified according to tumor stage, the Leu/Leu genotype of GPX1 was more frequently observed in bladder cancer patients with high-stage tumors than those with low-stage tumors. "
2.	Tics (Tic) 11/01/2009 - "Here, we investigated two of such inhibitors, the Benzyloxicarbonyl-Leu-Leu-Nle-CHO (LLNle) and the N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), to assess whether they were effective in killing human glioblastoma tumor-initiating cells (GBM TIC) in vitro. "
3.	Hallucinations (Hallucination) 09/01/2008 - "In addition, patients who were phe carriers (N=144) had significantly greater severity of positive symptoms (hallucinations) compared to patients who were leu/leu homozygotes (N=56). "
4.	Glioblastoma (Glioblastoma Multiforme) 11/01/2009 - "Here, we investigated two of such inhibitors, the Benzyloxicarbonyl-Leu-Leu-Nle-CHO (LLNle) and the N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), to assess whether they were effective in killing human glioblastoma tumor-initiating cells (GBM TIC) in vitro. "
5.	Prostatic Neoplasms (Prostate Cancer) 06/01/2011 - "Our results suggest that the HPC/ELAC-2 polymorphisms, especially in localized cases, could help to predict prostate cancer risk and confirm its high prevalence of the leu/leu allele in north Indian population. " 02/04/2013 - "A competitive inhibition study revealed that peptide transporters in prostate cancer cells exhibited broad substrate specificity with a preference for hydrophobic dipeptides, such as Leu-Leu. " 09/01/2006 - "The decreased risk we observed with the hOGG1 326 Cys/Cys genotype confirms an earlier report and the further reduced risk found with the CYP1B1 (432 Leu/Leu or Leu/Val)-hOGG1 (326 Cys/Cys)-XRCC1 (Arg/Arg or Arg/Gln) genotype combination may lend new insights to the importance of ROS generated from non-receptor-mediated estrogenic mechanisms in more aggressive prostate cancer." 07/01/2012 - "Overall, no significant association was found between the CYP1B1 Leu432Val polymorphism and prostate cancer susceptibility for Val/Val vs Leu/Leu (OR = 1.07; 95% CI: 0.79-1.44; P = 0.67), Leu/Val vs Leu/Leu (OR = 1.05; 95% CI: 0.94-1.17; P = 0.42), Leu/Val + Val/Val vs Leu/Leu (OR = 1.07; 95% CI: 0.91-1.26; P = 0.40) and Val/Val vs Leu/Val + Leu/Leu (OR = 1.11; 95% CI: 0.86-1.44; P = 0.43). "

Related Drugs and Biologics

1.	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))
2.	valylleucine
3.	valylvaline (Val-Val)
4.	Dipeptides
5.	peptide permease
6.	cytochrome P-450 CYP1B1 (CYP1B1)
7.	prolyl-proline (Pro-Pro)
8.	leucyl-leucine-methyl ester
9.	Proteasome Endopeptidase Complex (Proteasome)
10.	prolylleucine

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Intranasal Administration